Enanta Pharmaceuticals (ENTA) Competitors

$11.07 -0.21 (-1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$11.07 0.00 (0.00%)

As of 04:10 PM Eastern

ENTA vs. AVBP, PGEN, INBX, ARDX, and SEPN

Should you buy Enanta Pharmaceuticals stock or one of its competitors? MarketBeat compares Enanta Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enanta Pharmaceuticals include ArriVent BioPharma (AVBP), Precigen (PGEN), Inhibrx Biosciences (INBX), Ardelyx (ARDX), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ArriVent BioPharma has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. ArriVent BioPharma's return on equity of -48.98% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

ArriVent BioPharma presently has a consensus target price of $43.38, indicating a potential upside of 42.21%. Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 83.25%. Given Enanta Pharmaceuticals' higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Enanta Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A

ArriVent BioPharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, ArriVent BioPharma had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 1 mentions for ArriVent BioPharma and 0 mentions for Enanta Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.32 beat Enanta Pharmaceuticals' score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ArriVent BioPharma	Positive
Enanta Pharmaceuticals	Neutral

Summary

ArriVent BioPharma beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Precigen?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Enanta Pharmaceuticals currently has a consensus price target of $20.29, indicating a potential upside of 83.25%. Precigen has a consensus price target of $12.50, indicating a potential upside of 250.14%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 47.1% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Enanta Pharmaceuticals has a net margin of -89.56% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Precigen	-646.99%	717.50%	58.48%

Enanta Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Precigen has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Enanta Pharmaceuticals has higher revenue and earnings than Precigen. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A
Precigen	$9.68M	131.48	-$250.64M	-$1.18	N/A

In the previous week, Precigen had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Precigen and 0 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.00 beat Precigen's score of -0.57 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Precigen	Negative

Summary

Precigen beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Inhibrx Biosciences has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Enanta Pharmaceuticals presently has a consensus target price of $20.29, indicating a potential upside of 83.25%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 68.29%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enanta Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Enanta Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A
Inhibrx Biosciences	$1.30M	1,005.80	-$140.05M	-$8.39	N/A

In the previous week, Enanta Pharmaceuticals' average media sentiment score of 0.00 equaled Inhibrx Biosciences'average media sentiment score.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Inhibrx Biosciences	Neutral

Enanta Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.33, indicating that its share price is 233% more volatile than the broader market.

Summary

Enanta Pharmaceuticals beats Inhibrx Biosciences on 9 of the 14 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Ardelyx?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Enanta Pharmaceuticals currently has a consensus price target of $20.29, indicating a potential upside of 83.25%. Ardelyx has a consensus price target of $15.70, indicating a potential upside of 183.39%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Ardelyx has a net margin of -13.58% compared to Enanta Pharmaceuticals' net margin of -89.56%. Ardelyx's return on equity of -38.11% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Ardelyx had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for Ardelyx and 0 mentions for Enanta Pharmaceuticals. Ardelyx's average media sentiment score of 1.06 beat Enanta Pharmaceuticals' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Ardelyx	Positive

Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Ardelyx has higher revenue and earnings than Enanta Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A
Ardelyx	$407.32M	3.36	-$61.60M	-$0.23	N/A

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ardelyx beats Enanta Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Septerna?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Septerna has a net margin of -49.88% compared to Enanta Pharmaceuticals' net margin of -89.56%. Septerna's return on equity of -12.72% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Septerna	-49.88%	-12.72%	-8.87%

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Septerna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Septerna has lower revenue, but higher earnings than Enanta Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A
Septerna	$45.95M	29.83	-$48.88M	-$0.81	N/A

In the previous week, Septerna had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for Septerna and 0 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.00 beat Septerna's score of -0.03 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Septerna	Neutral

Enanta Pharmaceuticals currently has a consensus target price of $20.29, suggesting a potential upside of 83.25%. Septerna has a consensus target price of $45.00, suggesting a potential upside of 47.98%. Given Enanta Pharmaceuticals' higher probable upside, equities research analysts plainly believe Enanta Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Enanta Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Septerna has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market.

Summary

Septerna beats Enanta Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$328M	$2.94B	$6.43B	$12.05B
Dividend Yield	N/A	1.69%	2.67%	5.56%
P/E Ratio	-4.27	17.68	23.75	23.75
Price / Sales	4.93	296.71	479.99	83.74
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	3.65	3.83	10.28	6.78
Net Income	-$81.89M	$75.85M	$3.57B	$337.51M
7 Day Performance	-12.63%	-4.52%	-1.43%	-2.72%
1 Month Performance	-27.84%	-5.85%	3.27%	1.87%
1 Year Performance	48.19%	15.31%	23.37%	26.61%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	1.8096 of 5 stars	$11.07 -1.9%	$20.29 +83.2%	+51.0%	$328M	$65.32M	N/A	160
AVBP ArriVent BioPharma	2.5461 of 5 stars	$29.92 -2.5%	$43.38 +45.0%	+29.0%	$1.39B	N/A	N/A	40
PGEN Precigen	2.5828 of 5 stars	$3.86 -6.3%	$12.50 +223.8%	+138.7%	$1.38B	$9.68M	N/A	190	High Trading Volume
INBX Inhibrx Biosciences	2.241 of 5 stars	$93.63 -5.7%	$150.00 +60.2%	+525.1%	$1.37B	$1.30M	N/A	166	Gap Up
ARDX Ardelyx	3.0263 of 5 stars	$5.52 -3.7%	$15.70 +184.4%	+51.1%	$1.36B	$427.68M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. AVBP, PGEN, INBX, ARDX, and SEPN

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Summary

How does Enanta Pharmaceuticals compare to Precigen?

Summary

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does Enanta Pharmaceuticals compare to Ardelyx?

Summary

How does Enanta Pharmaceuticals compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. AVBP, PGEN, INBX, ARDX, and SEPN

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Do insiders and institutionals believe in AVBP or ENTA?

Is AVBP or ENTA more profitable?

Do analysts prefer AVBP or ENTA?

Which has preferable earnings & valuation, AVBP or ENTA?

Which has more volatility and risk, AVBP or ENTA?

Does the media favor AVBP or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Precigen?

Do analysts rate ENTA or PGEN?

Do insiders & institutionals believe in ENTA or PGEN?

Is ENTA or PGEN more profitable?

Which has more risk & volatility, ENTA or PGEN?

Which has stronger valuation & earnings, ENTA or PGEN?

Does the media favor ENTA or PGEN?

Summary

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Do institutionals and insiders believe in ENTA or INBX?

Is ENTA or INBX more profitable?

Do analysts recommend ENTA or INBX?

Which has higher earnings & valuation, ENTA or INBX?

Does the media refer more to ENTA or INBX?

Which has more volatility and risk, ENTA or INBX?

Summary

How does Enanta Pharmaceuticals compare to Ardelyx?

Do analysts rate ENTA or ARDX?

Is ENTA or ARDX more profitable?

Does the media favor ENTA or ARDX?

Which has more volatility and risk, ENTA or ARDX?

Which has higher valuation and earnings, ENTA or ARDX?

Do institutionals & insiders believe in ENTA or ARDX?

Summary

How does Enanta Pharmaceuticals compare to Septerna?

Is ENTA or SEPN more profitable?

Do institutionals and insiders believe in ENTA or SEPN?

Which has higher earnings and valuation, ENTA or SEPN?

Does the media favor ENTA or SEPN?

Do analysts prefer ENTA or SEPN?

Which has more risk and volatility, ENTA or SEPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools